• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF.

作者信息

Wang Hongquan, Wu Shuang, Wang Yan, Tang Bo

机构信息

Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.

出版信息

Cancer Biol Med. 2022 Jul 21;19(7):945-7. doi: 10.20892/j.issn.2095-3941.2022.0299.

DOI:10.20892/j.issn.2095-3941.2022.0299
PMID:35856565
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9334757/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ac1/9334757/d8590c086506/cbm-19-945-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ac1/9334757/d8590c086506/cbm-19-945-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ac1/9334757/d8590c086506/cbm-19-945-g001.jpg

相似文献

1
Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF.罗格列酮通过激活肿瘤抑制因子ESE3/EHF来阻断胰腺导管腺癌的进展。
Cancer Biol Med. 2022 Jul 21;19(7):945-7. doi: 10.20892/j.issn.2095-3941.2022.0299.
2
ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.ESE3/EHF，罗格列酮的一个有前途的靶点，通过下调 CXCR4 抑制胰腺癌干性。
Gut. 2022 Feb;71(2):357-371. doi: 10.1136/gutjnl-2020-321952. Epub 2021 Mar 5.
3
ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features.ESE3/EHF 控制上皮细胞分化，其缺失导致具有间质和干细胞样特征的前列腺肿瘤。
Cancer Res. 2012 Jun 1;72(11):2889-900. doi: 10.1158/0008-5472.CAN-12-0212. Epub 2012 Apr 13.
4
The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment.ETS因子ESE3/EHF可抑制白细胞介素-6，阻止信号转导和转录激活因子3（STAT3）的激活以及前列腺癌干细胞样细胞群的扩增。
Oncotarget. 2016 Nov 22;7(47):76756-76768. doi: 10.18632/oncotarget.12525.
5
Activation of the Lin28/let-7 Axis by Loss of ESE3/EHF Promotes a Tumorigenic and Stem-like Phenotype in Prostate Cancer.Lin28/let-7 轴的激活通过 ESE3/EHF 的缺失促进前列腺癌的致瘤和干细胞样表型。
Cancer Res. 2016 Jun 15;76(12):3629-43. doi: 10.1158/0008-5472.CAN-15-2665. Epub 2016 May 2.
6
Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2 Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy.用硝呋替莫靶向 ESE3/EHF 抑制 CXCR2 中性粒细胞浸润并克服胰腺癌对化疗和免疫治疗的耐药性。
Gastroenterology. 2024 Jul;167(2):281-297. doi: 10.1053/j.gastro.2024.02.046. Epub 2024 Mar 15.
7
Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.肿瘤性 EHF 可预测胰腺导管腺癌中抗 PD-1 治疗的疗效。
J Exp Med. 2019 Mar 4;216(3):656-673. doi: 10.1084/jem.20180749. Epub 2019 Feb 7.
8
The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma.ESE3/EHF的核凝聚物在胰腺导管腺癌中诱导细胞衰老，且不伴有相关的炎症分泌表型。
Cancer Lett. 2024 Dec 20;611:217408. doi: 10.1016/j.canlet.2024.217408.
9
ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin.ESE3通过上调E-钙黏蛋白抑制胰腺癌转移。
Cancer Res. 2017 Feb 15;77(4):874-885. doi: 10.1158/0008-5472.CAN-16-2170. Epub 2016 Dec 6.
10
Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression.蛋白酶体抑制剂MG132通过增加ESE3表达来抑制胰腺导管腺癌细胞迁移。
Oncol Lett. 2020 Jan;19(1):858-868. doi: 10.3892/ol.2019.11157. Epub 2019 Nov 28.

引用本文的文献

1
Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma.核 PLD1 与 NPM1 通过胰腺腺癌中的致瘤性 IL7R 诱导吉西他滨耐药。
Cancer Biol Med. 2023 Jun 27;20(8):599-626. doi: 10.20892/j.issn.2095-3941.2023.0039.

本文引用的文献

1
Arl4c promotes the growth and drug resistance of pancreatic cancer by regulating tumor-stromal interactions.Arl4c通过调节肿瘤-基质相互作用促进胰腺癌的生长和耐药性。
iScience. 2021 Nov 3;24(12):103400. doi: 10.1016/j.isci.2021.103400. eCollection 2021 Dec 17.
2
Stem Cells in the Exocrine Pancreas during Homeostasis, Injury, and Cancer.稳态、损伤和癌症过程中外分泌胰腺中的干细胞
Cancers (Basel). 2021 Jun 30;13(13):3295. doi: 10.3390/cancers13133295.
3
Cancer stem cell-immune cell crosstalk in tumour progression.肿瘤进展中的癌症干细胞-免疫细胞串扰。
Nat Rev Cancer. 2021 Aug;21(8):526-536. doi: 10.1038/s41568-021-00366-w. Epub 2021 Jun 8.
4
New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer growth.新型高通量筛选检测出可抑制胰腺星状细胞活化并减缓胰腺癌生长的化合物。
Pancreatology. 2021 Sep;21(6):1071-1080. doi: 10.1016/j.pan.2021.04.002. Epub 2021 Apr 20.
5
ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.ESE3/EHF，罗格列酮的一个有前途的靶点，通过下调 CXCR4 抑制胰腺癌干性。
Gut. 2022 Feb;71(2):357-371. doi: 10.1136/gutjnl-2020-321952. Epub 2021 Mar 5.
6
Future directions in drug development in pancreatic cancer.胰腺癌药物研发的未来方向
Semin Oncol. 2021 Feb;48(1):47-56. doi: 10.1053/j.seminoncol.2021.02.002. Epub 2021 Feb 23.
7
An emerging role for cellular crosstalk in the cancer stem cell niche.细胞串扰在肿瘤干细胞龛中的新作用。
J Pathol. 2021 Jul;254(4):384-394. doi: 10.1002/path.5655. Epub 2021 Mar 18.
8
The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives.星状细胞在胰腺导管腺癌中的作用：靶向治疗前景
Front Oncol. 2021 Jan 14;10:621937. doi: 10.3389/fonc.2020.621937. eCollection 2020.
9
Ese-3 contributes to colon cancer progression by downregulating EHD2 and transactivating INPP4B.Ese-3 通过下调 EHD2 和反式激活 INPP4B 促进结肠癌进展。
Am J Cancer Res. 2021 Jan 1;11(1):92-107. eCollection 2021.
10
Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma.上皮组织特异性转录因子 ESE3 在肝细胞癌中的表达及预后意义。
Int J Clin Oncol. 2020 Jul;25(7):1334-1345. doi: 10.1007/s10147-020-01675-0. Epub 2020 Apr 28.